On May 11, 2026, Gary K. Lee, the Chief Scientific Officer at Lyell Immunopharma, Inc. (NASDAQ: LYEL), executed a sale of company stock. The transaction involved the disposal of 130 shares of common stock, generating total proceeds of $2,459. The shares were liquidated at prices fluctuating between $18.91 and $19.30 per share, resulting in a weighted average sale price of $18.92. Lyell Immunopharma disclosed that these shares were automatically sold to cover tax withholding obligations associated with the settlement of vested restricted stock units.
Following this transaction, Mr. Lee's direct ownership position in Lyell Immunopharma common stock stands at 17,808 shares. It is important to note that this total includes 1,000 shares acquired on May 18, 2026, through the Issuer’s 2021 Employee Stock Purchase Plan. The insider sale activity occurs as Lyell Immunopharma, a biotech company valued at approximately $315 million, trades at $13.55 per share. This market price sits slightly above InvestingPro’s Fair Value estimate, which may suggest that the stock is currently overvalued at these levels.
Financial metrics for the company indicate significant challenges. Lyell Immunopharma posted a loss of $13.06 per share over the last twelve months. According to InvestingPro analysis, the company continues to burn through cash, a critical factor for investors monitoring unit economics and cash flow sustainability in the biotech sector. This analysis offers 12 additional ProTips for LYEL investors to consider when evaluating the firm's financial health.
In other recent developments, Lyell Immunopharma presented safety and translational data from its Phase 1/2 clinical trial of rondecabtagene autoleucel. The trial focuses on patients with relapsed or refractory large B-cell lymphoma. The company reported a manufacturing success rate of 97% across 108 patients treated with the therapy. Additionally, Lyell amended its colorectal cancer trial after implementing a gastrointestinal prophylaxis regimen. This adjustment reduced significant side effects, potentially allowing for an expansion into a Phase 2 trial.
Analyst sentiment surrounding Lyell Immunopharma remains mixed but leans positive. Citizens maintained a Market Outperform rating on Lyell Immunopharma with a $34.00 price target, citing clinical progress and financial stability. H.C. Wainwright reiterated a Buy rating with a $45.00 price target following updated safety data from the colorectal cancer program. The safety dataset addressed previous concerns, showing a reduction in treatment-related side effects.
Market data for LYEL shows a closing price of 13.55, up 0.050 (+0.37%) at 15:59:59 USD. In after-hours trading, the stock dropped to 12.906, down 0.644 (-4.75%) at 17:56:57. These developments reflect ongoing clinical advancements and positive analyst sentiment surrounding Lyell Immunopharma’s trials and financial outlook.